Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019–2021

Keyphrases

• Taiwan 100%
• Clostridioides Difficile 100%
• Ribotyping 100%
• Antimicrobial Susceptibility Profile 100%
• Laboratory-based Surveillance 100%
• Difficile 66%
• Ribotype 078 66%
• Vancomycin 50%
• Fidaxomicin 50%
• Metronidazole 33%
• Clindamycin 33%
• Rifaximin 33%
• Central Taiwan 16%
• Moxifloxacin 16%
• Resistance Rate 16%
• Medical Center 16%
• Genetic Diversity 16%
• Antimicrobial Susceptibility 16%
• MIC90 16%
• In Vitro Susceptibility 16%
• Susceptibility Rate 16%
• Metronidazole Resistance 16%
• Clostridium Difficile Infection 16%
• Zoonotic Potential 16%
• TcdA 16%
• Genetic Relatedness 16%
• Ribotype 017 16%
• Ribotype 027 16%
• Reference Laboratory 16%
• Treatment Burden 16%

Medicine and Dentistry

• Vancomycin 100%
• Metronidazole 100%
• Antibiogram 100%
• Fidaxomicin 100%
• In Vitro 66%
• Rifaximin 66%
• Clindamycin 66%
• Infection 33%
• Genetic Variability 33%
• Ribotyping 33%
• Moxifloxacin 33%

Immunology and Microbiology

• Antibiotic Sensitivity 100%
• MIC90 50%
• Genetic Variability 50%
• Ribotyping 50%
• Zoonotic 50%